Structure Therapeutics Inc.
GPCRHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs. At a $1.51B market cap, Structure Therapeutics Inc. ranks as a small-cap company within healthcare. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Market Cap
$1.51B
Beta
-1.37
P/E (TTM)
—
P/E (Fwd)
-10.03
EPS (TTM)
$-3.03
EPS (Fwd)
$-2.11
ROE
-20.2%
ROA
-14.9%
Cash
$1.34B
Total Debt
$6.2M
Free CF
-$119.1M
52W Change
-26.0%
Annual Financials
Cash vs Debt
Where GPCR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GPCR finished 50.01% below its 150-day moving average ($44.03) and 57.03% below its 200-day moving average ($51.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GPCR overbought or oversold?
At the October 20, 2026 close, GPCR's RSI(14) was 9.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.34B in cash comfortably exceeding the $6.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$119.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -20.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
GPCR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Structure Therapeutics Inc. and its sector.